Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Thomas Winkler, Xing Fan, James Cooper, Ronan Desmond, David J. Young, Danielle M. Townsley, Phillip Scheinberg, Sophia Grasmeder, Andre Larochelle, Marie Desierto, Janet Valdez, Jennifer Lotter, Colin Wu, Ruba N. Shalhoub, Katherine R. Calvo, Neal S. Young, Cynthia E. Dunbar

Blood (2019) 133 (24): 2575–2585.

https://doi.org/10.1182/blood.2019000478

Published: 2019

Journal Articles

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Xing Fan, MD, Thomas Winkler, MD, Ronan Desmond, MD, Bogdan Dumitriu, MD, Danielle M. Townsley, MD MSc, Maria del Pilar Fernandez Ibanez, Fernanda Gutierrez-Rodrigues, PhD, Sophia Grasmeder, RN, Ma Evette Barranta, Diane Madey, Jennifer Lotter, Janet Valdez, Katherine R. Calvo, MD PhD, Colin Wu, PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2018) 132 (Supplement 1): 538.

https://doi.org/10.1182/blood-2018-99-112994

Published: 2018

Journal Articles

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Thomas Winkler, MD, James N. Cooper, MD, Danielle M. Townsley, MDMSc, Phillip Scheinberg, MD, Sophia Grasmeder, RN, Colin Wu, PhD, Jennifer Lotter, Marie J Desierto, MS, Ronan Desmond, MD, Matthew J. Olnes, MD PhD, Katherine R Calvo, MD PhD, Neal S. Young, MD, Cynthia E Dunbar, MD

Blood (2017) 130 (Supplement 1): 777.

https://doi.org/10.1182/blood.V130.Suppl_1.777.777

Published: 2017

Journal Articles

Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag

Thomas Winkler, MD, Danielle Townsley, MD, Ronan Desmond, MD FRCPath, Bogdan Dumitriu, MD, Sophia Grasmeder, RN, BSN, OCN, Neal S. Young, Cynthia E. Dunbar, MD

Blood (2016) 128 (22): 2682.

https://doi.org/10.1182/blood.V128.22.2682.2682

Published: 2016

Journal Articles

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Robert N Reger, Maria Berg, Andreas Lundqvist, PhD, Theresa Donohue, MHS, PA-C, Mattias Carlsten, MD Ph.D, Dawn M Betters, Ph.D, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Su Su, MD, PhD, David Stroncek, MD, Jeremy Pantin, MD, Keyvan Keyvanfar, BS, Cristian A. Carvallo, MD, Hahn Khuu, MD, Richard Childs, MD

Blood (2011) 118 (21): 1001.

https://doi.org/10.1182/blood.V118.21.1001.1001

Published: 2011

Journal Articles

In Vitro Assessment of Tolerance and Rejection Occurring After Co-Transplantation of Allogeneic Umbilical Cord Blood and Haploidentical CD34+ Cells as Treatment for Severe Aplastic Anemia

Nicole J. Gormley, MD, Aleah Smith, Maria Berg, Lisa Cook, RN, BSN, Catalina Ramos, RN, Sophia Grasmeder, RN, BSN, OCN, Theresa Donohue, MHS, PA-C, Richard Childs, MD

Blood (2010) 116 (21): 2352.

https://doi.org/10.1182/blood.V116.21.2352.2352

Published: 2010

Journal Articles

Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria

Jeremy Pantin, MD, Xin Tian, Nancy Geller, PhD, Catalina Ramos, CRN, Lisa Cook, CRN, Sophia Grasmeder, CRN, Philip Scheinberg, MD, Neal S. Young, MD, Sumithira Vasu, MD, Theresa Donohue, MHS, PA-C, Richard Childs, MD

Blood (2010) 116 (21): 3505.

https://doi.org/10.1182/blood.V116.21.3505.3505

Published: 2010

Journal Articles

Absence of Graft Failure and Excellent Long Term Survival Following Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation In Heavily Transfused Patients with ATG-Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Jeremy Pantin, MD, Xin Tian, Ph.D., Nancy Geller, Ph.D., Catalina Ramos, CRN, Lisa Cook, CRN, Sophia Grasmeder, CRN, Philip Scheinberg, MD, Neal S. Young, MD, Sumithira Vasu, MD, Theresa Donohue, MHS, PA-C, Richard Childs, MD

Blood (2010) 116 (21): 517.

https://doi.org/10.1182/blood.V116.21.517.517

Published: 2010

Journal Articles

Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity

Aleah Smith, Hahn Khuu, MD, Dawn M Betters, RN, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Maria Berg, Rebecca Lopez, PhD, Su Su, MD, PhD, Vicki Fellowes, MT, David Stroncek, MD, Jeremy Pantin, MD, Sumi Vasu, MD, Theresa Donohue, MHS, PA-C, Keyvan Keyvanfar, BS, Richard Childs, MD

Blood (2010) 116 (21): 4296.

https://doi.org/10.1182/blood.V116.21.4296.4296

Published: 2010

NARROW

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

In Vitro Assessment of Tolerance and Rejection Occurring After Co-Transplantation of Allogeneic Umbilical Cord Blood and Haploidentical CD34+ Cells as Treatment for Severe Aplastic Anemia

Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria

Absence of Graft Failure and Excellent Long Term Survival Following Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation In Heavily Transfused Patients with ATG-Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only